Nabi BioPharm Begins Study on Nicotine Vaccine

Nabi Biopharmaceuticals announced that it is participating in an investigator initiated Phase IIb study to evaluate the safety and efficacy of NicVAX(R) (Nicotine Conjugate Vaccine) when co-administered with varenicline as an aid to smoking
cessation and relapse prevention. This study will be conducted by The Research
School CAPHRI of the Maastricht University Medical Center in Maastricht, The
Netherlands and will be funded primarily by The Netherlands Organization for
Health Research and Development and Maastricht University with Nabi providing
some additional support.

"In our proof-of-concept trial, NicVAX demonstrated that high levels of
anti-nicotine antibody in response to NicVAX immunization increases the ability
of smokers to quit smoking and remain abstinent," said Dr. Raafat Fahim,
President and Chief Executive Officer of Nabi Biopharmaceuticals.

For more on NicVax, please click here.

Share this article with your social network, just click below to share now!

Share |